19:02 , Feb 24, 2017 |  BC Week In Review  |  Financial News

Arch Therapeutics completes direct public offering

On Feb. 21, hemostasis company Arch Therapeutics Inc. (OTCQB:ARTH) raised $6.1 million through the sale of 10.2 million units at $0.60 in a registered direct offering with six accredited investors. Each unit comprises a share...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

AC5 Surgical Hemostatic Device: Clinical trial data

Top-line data from a single-blind, Irish clinical trial in 46 patients with bleeding wounds due to >=2 skin lesion excisions showed that topical AC5 administered by the AC5 Surgical Hemostatic Device met the primary endpoint...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Arch Therapeutics Inc management update

Arch Therapeutics Inc . (OTCQB:ARTH), Wellesley, Mass.   Business: Hematology   Hired: Richard Davis as CFO and treasurer, formerly president, COO and CFO of NMT Medical Inc.; he replaces Alan Barber, who resigned  ...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Financial News

Arch Therapeutics completes private placement of common stock and warrants

Arch Therapeutics Inc. (OTCQB:ARTH), Wellesley, Mass.   Business: Hematology   Date completed: 2/10/14   Type: Private placement of common stock and warrants   Raised: $2.9 million   Shares: 11.4 million   Price: $0.25   Shares...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Financial News

Arch Therapeutics proposes debt financing

Arch Therapeutics Inc. (OTCQB: ARTH), Wellesley, Mass.   Business: Hematology   Date announced: 10/7/13   Type: Debt financing   To be raised: $1 million   Investors: Massachusetts Life Sciences Center   Note: The unsecured, subordinated...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Arch Therapeutics deal

Arch Therapeutics (formerly Almah Inc.) reverse-merged with Arch Biosurgery Inc., with Arch Therapeutics remaining as the surviving entity. The company's AC5 is in preclinical development to achieve hemostasis in minimally invasive and open surgical procedures....
07:00 , May 5, 2008 |  BC Week In Review  |  Company News

Arch Therapeutics, Massachusetts Institute of Technology deal

The institute granted Arch worldwide rights to develop and commercialize a range of patents and applications for technology that includes a family of compositions to stop and prevent bleeding. Arch received exclusive rights to hemostasis...